;PMID: 7488489
;source_file_1901.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..207] = [t:41..207]
;2)section:[e:211..255] = [t:211..255]
;3)section:[e:259..378] = [t:259..378]
;4)sentence:[e:382..527] = [t:382..527]
;5)sentence:[e:528..650] = [t:528..650]
;6)sentence:[e:651..714] = [t:651..714]
;7)sentence:[e:715..894] = [t:715..894]
;8)sentence:[e:895..975] = [t:895..975]
;9)sentence:[e:976..1142] = [t:976..1142]
;10)sentence:[e:1143..1264] = [t:1143..1264]
;11)sentence:[e:1265..1419] = [t:1265..1419]
;12)sentence:[e:1420..1607] = [t:1420..1607]
;13)section:[e:1611..1655] = [t:1611..1655]

;section 0 Span:0..35
;Br J Anaesth. 1995 Oct;75(4):462-6.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..12] Anaesth) (.:[12..13] .)
        (CD:[14..18] 1995) (.:[19..25] Oct;75) (-LRB-:[25..26] -LRB-)
        (CD:[26..27] 4) (-RRB-:[27..28] -RRB-) (CD:[28..35] :462-6.)))

;sentence 1 Span:41..207
;Difference between in vivo and in vitro effects of propofol on defluorination
; and metabolic activities of hamster hepatic cytochrome P450-dependent 
;mono-oxygenases.
;[92..100]:substance:"propofol"
;[164..179]:cyp450:"cytochrome P450"
;[191..206]:substance:"mono-oxygenases"
(SENT
  (NP-HLN
    (NP (NN:[41..51] Difference))
    (PP (IN:[52..59] between)
      (NP
        (NP
          (NP
            (NP
              (ADJP (FW:[60..62] in) (FW:[63..67] vivo))
              (NML-2 (-NONE-:[67..67] *P*)))
            (CC:[68..71] and)
            (NP
              (ADJP (FW:[72..74] in) (FW:[75..80] vitro))
              (NML-2 (NNS:[81..88] effects))))
          (PP (IN:[89..91] of)
            (NP (NN:[92..100] propofol))))
        (PP (IN:[101..103] on)
          (NP
            (NP
              (NP (NN:[104..118] defluorination))
              (CC:[120..123] and)
              (NP (JJ:[124..133] metabolic) (NNS:[134..144] activities)))
            (PP (IN:[145..147] of)
              (NP (NN:[148..155] hamster) (JJ:[156..163] hepatic)
                (NML
                  (NML (NN:[164..174] cytochrome) (NN:[175..179] P450))
                  (HYPH:[179..180] -) (JJ:[180..189] dependent))
                 (AFX:[191..195] mono) (HYPH:[195..196] -)
                 (NNS:[196..206] oxygenases)))))))
    (.:[206..207] .)))

;section 2 Span:211..255
;Chen TL, Wang MJ, Huang CH, Liu CC, Ueng TH.
(SEC
  (FRAG (NNP:[211..215] Chen) (NNP:[216..218] TL) (,:[218..219] ,)
        (NNP:[220..224] Wang) (NNP:[225..227] MJ) (,:[227..228] ,)
        (NNP:[229..234] Huang) (NNP:[235..237] CH) (,:[237..238] ,)
        (NNP:[239..242] Liu) (NNP:[243..245] CC) (,:[245..246] ,)
        (NNP:[247..251] Ueng) (NNP:[252..254] TH) (.:[254..255] .)))

;section 3 Span:259..378
;Department of Anaesthesia, College of Medicine, National Taiwan University 
;Hospital, No. 7, Taipei, Republic of China.
(SEC
  (FRAG (NNP:[259..269] Department) (IN:[270..272] of)
        (NNP:[273..284] Anaesthesia) (,:[284..285] ,) (NNP:[286..293] College)
        (IN:[294..296] of) (NNP:[297..305] Medicine) (,:[305..306] ,)
        (NNP:[307..315] National) (NNP:[316..322] Taiwan)
        (NNP:[323..333] University) (NNP:[335..343] Hospital) (,:[343..344] ,)
        (NNP:[345..347] No) (.:[347..348] .) (CD:[349..350] 7) (,:[350..351] ,)
        (NNP:[352..358] Taipei) (,:[358..359] ,) (NNP:[360..368] Republic)
        (IN:[369..371] of) (NNP:[372..377] China) (.:[377..378] .)))

;sentence 4 Span:382..527
;We have compared the in vivo and in vitro effects of propofol on cytochrome 
;P450-dependent monooxygenase activities in hamster liver microsomes.
;[435..443]:substance:"propofol"
;[447..463]:cyp450:"cytochrome  P450"
;[474..487]:substance:"monooxygenase"
(SENT
  (S
    (NP-SBJ (PRP:[382..384] We))
    (VP (VBP:[385..389] have)
      (VP (VBN:[390..398] compared)
        (NP
          (NP (DT:[399..402] the)
            (NML
              (NML
                (ADJP (FW:[403..405] in) (FW:[406..410] vivo))
                (NML-1 (-NONE-:[410..410] *P*)))
              (CC:[411..414] and)
              (NML
                (ADJP (FW:[415..417] in) (FW:[418..423] vitro))
                (NML-1 (NNS:[424..431] effects)))))
          (PP (IN:[432..434] of)
            (NP (NN:[435..443] propofol)))
          (PP (IN:[444..446] on)
            (NP
              (ADJP
                (NML (NN:[447..457] cytochrome) (NN:[459..463] P450))
                (HYPH:[463..464] -) (JJ:[464..473] dependent))
              (NN:[474..487] monooxygenase) (NNS:[488..498] activities))))
        (PP-LOC (IN:[499..501] in)
          (NP (NN:[502..509] hamster) (NN:[510..515] liver)
              (NNS:[516..526] microsomes)))))
    (.:[526..527] .)))

;sentence 5 Span:528..650
;Propofol  (Diprivan) 10 mg/100 g body weight was injected i.p. twice a day
;for 2 weeks to  induce cytochrome P450 enzymes.
;[528..536]:substance:"Propofol"
;[539..547]:substance:"Diprivan"
;[549..551]:quantitative-value:"10"
;[552..572]:quantitative-value:"mg/100 g body weight"
;[607..608]:quantitative-value:"2"
;[609..614]:quantitative-units:"weeks"
;[626..649]:cyp450:"cytochrome P450 enzymes"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (NN:[528..536] Propofol))
        (NP (-LRB-:[538..539] -LRB-) (NN:[539..547] Diprivan)
            (-RRB-:[547..548] -RRB-)))
      (NP-MNR
        (NP (CD:[549..551] 10) (NN:[552..554] mg))
        (PP (SYM:[554..555] /)
          (NP
            (NML (CD:[555..558] 100) (NN:[559..560] g))
            (NN:[561..565] body) (NN:[566..572] weight)))))
    (VP (VBD:[573..576] was)
      (VP (VBN:[577..585] injected)
        (NP-1 (-NONE-:[585..585] *))
        (ADVP (RB:[586..590] i.p.))
        (ADVP-TMP (RB:[591..596] twice)
          (NP (DT:[597..598] a) (NN:[599..602] day)))
        (PP-TMP (IN:[603..606] for)
          (NP (CD:[607..608] 2) (NNS:[609..614] weeks)))
        (S-PRP
          (NP-SBJ (-NONE-:[614..614] *))
          (VP (TO:[615..617] to)
            (VP (VB:[619..625] induce)
              (NP
                (NML (NN:[626..636] cytochrome) (NN:[637..641] P450))
                (NNS:[642..649] enzymes)))))))
    (.:[649..650] .)))

;sentence 6 Span:651..714
;Liver microsomes were prepared by differential  centrifugation.
(SENT
  (S
    (NP-SBJ-1 (NN:[651..656] Liver) (NNS:[657..667] microsomes))
    (VP (VBD:[668..672] were)
      (VP (VBN:[673..681] prepared)
        (NP-1 (-NONE-:[681..681] *))
        (PP-MNR (IN:[682..684] by)
          (NP (JJ:[685..697] differential) (NN:[699..713] centrifugation)))))
    (.:[713..714] .)))

;sentence 7 Span:715..894
;Metabolism of the cytochrome P450-dependent mono-oxygenase  system was
;evaluated by measuring aniline hydroxylation, benzphetamine  demethylation
;and benzo(a)pyrene hydroxylation.
;[733..748]:cyp450:"cytochrome P450"
;[759..773]:substance:"mono-oxygenase"
;[809..816]:substance:"aniline"
;[832..845]:substance:"benzphetamine"
;[865..879]:substance:"benzo(a)pyrene"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[715..725] Metabolism))
      (PP (IN:[726..728] of)
        (NP (DT:[729..732] the)
          (ADJP
            (NML (NN:[733..743] cytochrome) (NN:[744..748] P450))
            (HYPH:[748..749] -) (JJ:[749..758] dependent))
          (NML (AFX:[759..763] mono) (HYPH:[763..764] -)
               (NN:[764..773] oxygenase))
          (NN:[775..781] system))))
    (VP (VBD:[782..785] was)
      (VP (VBN:[786..795] evaluated)
        (NP-1 (-NONE-:[795..795] *))
        (PP-MNR (IN:[796..798] by)
          (S-NOM
            (NP-SBJ (-NONE-:[798..798] *))
            (VP (VBG:[799..808] measuring)
              (NP
                (NP (NN:[809..816] aniline) (NN:[817..830] hydroxylation))
                (,:[830..831] ,)
                (NP (NN:[832..845] benzphetamine) (NN:[847..860] demethylation))
                (CC:[861..864] and)
                (NP (NN:[865..879] benzo-LRB-a-RRB-pyrene)
                    (NN:[880..893] hydroxylation))))))))
    (.:[893..894] .)))

;sentence 8 Span:895..975
;Defluorination of enflurane was  assayed by detecting free fluoride
;metabolites.
;[913..922]:substance:"enflurane"
;[954..974]:substance:"fluoride metabolites"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[895..909] Defluorination))
      (PP (IN:[910..912] of)
        (NP (NN:[913..922] enflurane))))
    (VP (VBD:[923..926] was)
      (VP (VBN:[928..935] assayed)
        (NP-1 (-NONE-:[935..935] *))
        (PP-MNR (IN:[936..938] by)
          (S-NOM
            (NP-SBJ (-NONE-:[938..938] *))
            (VP (VBG:[939..948] detecting)
              (NP (JJ:[949..953] free)
                 (NN:[954..962] fluoride) (NNS:[963..974] metabolites)))))))
    (.:[974..975] .)))

;sentence 9 Span:976..1142
;At similar concentrations as in  the in vivo group, propofol in vitro
;exhibited concentration-dependent  inhibition of metabolism of benzphetamine
;and benzo(a)pyrene.
;[1028..1036]:substance:"propofol"
;[1109..1122]:substance:"benzphetamine"
;[1127..1141]:substance:"benzo(a)pyrene"
(SENT
  (S
    (PP (IN:[976..978] At)
      (NP
        (NP (JJ:[979..986] similar) (NNS:[987..1001] concentrations))
        (PP (IN:[1002..1004] as)
          (PP-LOC (IN:[1005..1007] in)
            (NP (DT:[1009..1012] the)
              (ADJP (FW:[1013..1015] in) (FW:[1016..1020] vivo))
              (NN:[1021..1026] group))))))
    (,:[1026..1027] ,)
    (NP-SBJ
      (NP (NN:[1028..1036] propofol))
      (ADJP (FW:[1037..1039] in) (FW:[1040..1045] vitro)))
    (VP (VBD:[1046..1055] exhibited)
      (NP
        (NP
          (ADJP (NN:[1056..1069] concentration) (HYPH:[1069..1070] -)
                (JJ:[1070..1079] dependent))
          (NN:[1081..1091] inhibition))
        (PP (IN:[1092..1094] of)
          (NP
            (NP (NN:[1095..1105] metabolism))
            (PP (IN:[1106..1108] of)
              (NP (NN:[1109..1122] benzphetamine) (CC:[1123..1126] and)
                  (NN:[1127..1141] benzo-LRB-a-RRB-pyrene)))))))
    (.:[1141..1142] .)))

;sentence 10 Span:1143..1264
;Aniline  hydroxylation and defluorination of enflurane were inhibited to 78%
;of control  with propofol 0.25 mmol litre-1.
;[1143..1150]:substance:"Aniline"
;[1188..1197]:substance:"enflurane"
;[1216..1219]:quantitative-value:"78%"
;[1237..1245]:substance:"propofol"
;[1246..1250]:quantitative-value:"0.25"
;[1251..1263]:quantitative-units:"mmol litre-1"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1143..1150] Aniline) (NN:[1152..1165] hydroxylation))
      (CC:[1166..1169] and)
      (NP
        (NP (NN:[1170..1184] defluorination))
        (PP (IN:[1185..1187] of)
          (NP (NN:[1188..1197] enflurane)))))
    (VP (VBD:[1198..1202] were)
      (VP (VBN:[1203..1212] inhibited)
        (NP-1 (-NONE-:[1212..1212] *))
        (PP-EXT (TO:[1213..1215] to)
          (NP
            (NP (CD:[1216..1218] 78) (NN:[1218..1219] %))
            (PP (IN:[1220..1222] of)
              (NP (NN:[1223..1230] control)))))
        (PP-MNR (IN:[1232..1236] with)
          (NP
            (NP (NN:[1237..1245] propofol))
            (NP
              (NML (CD:[1246..1250] 0.25) (NN:[1251..1255] mmol))
              (NN:[1256..1263] litre-1))))))
    (.:[1263..1264] .)))

;sentence 11 Span:1265..1419
;In propofol-treated hamsters, there was only  minimal inhibitory or inductive
;effects on either mono-oxygenase activities or  capacity for defluorination.
;[1268..1276]:substance:"propofol"
;[1361..1375]:substance:"mono-oxygenase"
(SENT
  (S
    (PP-LOC (IN:[1265..1267] In)
      (NP
        (ADJP (NN:[1268..1276] propofol) (HYPH:[1276..1277] -)
              (VBN:[1277..1284] treated))
        (NNS:[1285..1293] hamsters)))
    (,:[1293..1294] ,)
    (NP-SBJ (EX:[1295..1300] there))
    (VP (VBD:[1301..1304] was)
      (NP-PRD
        (NP (RB:[1305..1309] only)
          (NP
            (ADJP-1 (JJ:[1311..1318] minimal))
            (JJ:[1319..1329] inhibitory)
            (NML-2 (-NONE-:[1329..1329] *P*)))
          (CC:[1330..1332] or)
          (NP
            (ADJP-1 (-NONE-:[1332..1332] *P*))
            (JJ:[1333..1342] inductive)
            (NML-2 (NNS:[1343..1350] effects))))
        (PP (IN:[1351..1353] on)
          (NP (CC:[1354..1360] either)
            (NP
              (NML (AFX:[1361..1365] mono) (HYPH:[1365..1366] -)
                   (NN:[1366..1375] oxygenase))
              (NNS:[1376..1386] activities))
            (CC:[1387..1389] or)
            (NP
              (NP (NN:[1391..1399] capacity))
              (PP (IN:[1400..1403] for)
                (NP (NN:[1404..1418] defluorination))))))))
    (.:[1418..1419] .)))

;sentence 12 Span:1420..1607
;This difference between the in vitro and in vivo  effects of propofol on
;cytochrome P450 mono-oxygenase activities emphasizes the  need for care when
;comparing in vitro and clinical data.
;[1481..1489]:substance:"propofol"
;[1493..1508]:cyp450:"cytochrome P450"
;[1509..1523]:substance:"mono-oxygenase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1420..1424] This) (NN:[1425..1435] difference))
      (PP (IN:[1436..1443] between)
        (NP
          (NP (DT:[1444..1447] the)
            (NML
              (NML
                (ADJP (FW:[1448..1450] in) (FW:[1451..1456] vitro))
                (NML-2 (-NONE-:[1456..1456] *P*)))
              (CC:[1457..1460] and)
              (NML
                (ADJP (FW:[1461..1463] in) (FW:[1464..1468] vivo))
                (NML-2 (NNS:[1470..1477] effects)))))
          (PP (IN:[1478..1480] of)
            (NP (NN:[1481..1489] propofol)))
          (PP (IN:[1490..1492] on)
            (NP
              (NML (NN:[1493..1503] cytochrome) (NN:[1504..1508] P450))
              (NML (AFX:[1509..1513] mono) (HYPH:[1513..1514] -)
                   (NN:[1514..1523] oxygenase))
              (NNS:[1524..1534] activities))))))
    (VP (VBZ:[1535..1545] emphasizes)
      (NP
        (NP (DT:[1546..1549] the) (NN:[1551..1555] need))
        (PP (IN:[1556..1559] for)
          (NP (NN:[1560..1564] care))))
      (SBAR-ADV (WRB:[1565..1569] when)
        (S
          (NP-SBJ (-NONE-:[1569..1569] *))
          (VP (VBG:[1570..1579] comparing)
            (NP
              (ADJP (FW:[1580..1582] in) (FW:[1583..1588] vitro))
              (NML-1 (-NONE-:[1588..1588] *P*)))
            (CC:[1589..1592] and)
            (NP (JJ:[1593..1601] clinical)
              (NML-1 (NNS:[1602..1606] data)))))))
    (.:[1606..1607] .)))

;section 13 Span:1611..1655
;PMID: 7488489 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1611..1615] PMID) (::[1615..1616] :) (CD:[1617..1624] 7488489)
        (NN:[1625..1626] -LSB-) (NNP:[1626..1632] PubMed) (HYPH:[1633..1634] -)
        (NN:[1635..1642] indexed) (IN:[1643..1646] for)
        (NNP:[1647..1654] MEDLINE) (-RRB-:[1654..1655] -RSB-)))
